The customary treatment involves long term dosage of prednisone, alternated or combined with cytotoxic drugs, such as cyclophosphamide or azathioprine. Plasmapheresis may also be indicated in the acute setting to remove ANCA antibodies. Rituximab has been investigated, and in April 2011 approved by the FDA when used in combination with glucocorticoids in adult patients.
Microscopic polyangiitis
Granulomatosis with polyangiitis
Polyarteritis nodosa
Lupus vasculitis
Eosinophilic granulomatosis with polyangiitis
Thromboangiitis obliterans
Transplant glomerulopathy
Thin basement membrane disease